Platelet glycoprotein Ib alpha fusion polypeptides and methods of use thereof

Abstract

The present invention provides compositions and methods for treating or preventing vascular-associated disorders.

1 - 28 . (canceled)  
     
     
         29 . A method of inhibiting adherence of a platelet to von Willebrand Factor in a subject, the method comprising administering to a subject in need thereof a polypeptide comprising the amino acid sequence of SEQ ID NO:5 in an amount sufficient to inhibit adherence of said platelet to von Willebrand Factor.  
     
     
         30 - 46 . (canceled)  
     
     
         47 . A method of treating a disorder associated with platelet activation in a subject, the method comprising administering to a subject in need thereof a polypeptide comprising the amino acid sequence of SEQ ID NO:5.  
     
     
         48 . The method of  claim 47 , wherein said disorder is associated with thrombotic disease.  
     
     
         49 . The method of  claim 47 , wherein said disorder is ischemic heart disease, angina, acute myocardial infarction, stroke, venous thrombosis, atherosclerosis, restenosis, vascular inflammation or arterial thrombosis.  
     
     
         50 . The method of  claim 47 , wherein said disorder is angina.  
     
     
         51 . The method of  claim 50 , wherein said angina is unstable angina.  
     
     
         52 . The method of  claim 47 , wherein said subject is a human.  
     
     
         53 . The method of  claim 47 , further comprising administering to said subject a compound selected from the group consisting of acetylsalicylic acid, heparin, a glycoprotein IIb/IIIa antagonist, clopidogrel, a P-selectin antagonist, a thrombin inhibitor and a thrombolytic enzyme.  
     
     
         54 . The method of  claim 47 , wherein said disorder is ischemic heart disease.  
     
     
         55 . The method of  claim 47 , wherein said disorder is acute myocardial infarction.  
     
     
         56 . The method of  claim 47 , wherein said disorder is stroke.  
     
     
         57 . The method of  claim 47 , wherein said disorder is venous thrombosis.  
     
     
         58 . The method of  claim 47 , wherein said disorder is atherosclerosis.  
     
     
         59 . The method of  claim 47 , wherein said disorder is arterial thrombosis.  
     
     
         60 . The method of  claim 47 , wherein said disorder is restenosis.  
     
     
         61 . The method of  claim 60 , wherein said restenosis is angioplasty-related restenosis.  
     
     
         62 . The method of  claim 50 , wherein said angina is stable angina.  
     
     
         63 . The method of  claim 47 , wherein said disorder is vascular inflammation.  
     
     
         64 . The method of  claim 47 , further comprising administering to said subject acetylsalicylic acid.  
     
     
         65 . The method of  claim 47 , further comprising administering to said subject heparin.  
     
     
         66 . The method of  claim 47 , further comprising administering to said subject a glycoprotein IIb/IIIa antagonist.  
     
     
         67 . The method of  claim 47 , further comprising administering to said subject clopidogrel.  
     
     
         68 . The method of  claim 47 , further comprising administering to said subject a P-selectin antagonist.  
     
     
         69 . The method of  claim 47 , further comprising administering to said subject a thrombin inhibitor.  
     
     
         70 . The method of  claim 47 , further comprising administering to said subject a thrombolytic enzyme.  
     
     
         71 . The method of  claim 29 , wherein said subject is a human.  
     
     
         72 . The method of  claim 29 , wherein said subject is a primate.  
     
     
         73 . The method of  claim 47 , wherein said subject is a primate.  
     
     
         74 . The method of  claim 47 , wherein said polypeptide is a multimeric polypeptide.  
     
     
         75 . The method of  claim 74 , wherein said multimeric polypeptide is a dimer.  
     
     
         76 . The method of  claim 47 , wherein said polypeptide consists essentially of the amino acid sequence of SEQ ID NO:5.  
     
     
         77 . The method of  claim 47 , wherein said polypeptide consists of the amino acid sequence of SEQ ID NO:5.  
     
     
         78 . A method of inhibiting adherence of a platelet to von Willebrand Factor in a human, the method comprising administering to a human in need thereof a polypeptide that consists of the amino acid sequence of SEQ ID NO:5, wherein the polypeptide blocks von Willebrand Factor binding sites preventing platelet adherence whereby allowing for a reduced amount of restrained blood flow.